HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Limiting the extent of a delayed hemolytic transfusion reaction with automated red blood cell exchange.

Abstract
Delayed hemolytic transfusion reactions (DHTRs) are mediated by blood group antibodies that undergo anamnestic increases following antigen reexposure. Available options for the treatment or prophylaxis of DHTRs are limited. We report the use of automated red blood cell exchange (ARE) to limit hemolysis associated with an emerging DHTR. Following transfusion of 12 red blood cell units, a family member's comments led to the discovery of a patient's history of 4 alloantibodies (anti-E, anti-c, anti-Fy(a), and anti-M). Testing revealed that all 12 units were incompatible for at least 1 antigen. Six days after transfusion, the patient developed a newly positive antibody screen and direct antiglobulin test (DAT) result. To prevent further hemolysis, ARE was performed to replace incompatible red blood cells with antigen-negative units. After ARE, the patient's DAT results were negative and he was discharged without demonstrating symptoms of hemolysis. This case illustrates the use of ARE to limit hemolysis and prevent symptoms of a DHTR.
AuthorsChristopher A Tormey, Gary Stack
JournalArchives of pathology & laboratory medicine (Arch Pathol Lab Med) Vol. 137 Issue 6 Pg. 861-4 (Jun 2013) ISSN: 1543-2165 [Electronic] United States
PMID23721278 (Publication Type: Case Reports, Journal Article)
Topics
  • Aged
  • Automation
  • Blood Group Incompatibility (immunology, prevention & control)
  • Erythrocyte Transfusion (adverse effects)
  • Exchange Transfusion, Whole Blood (methods)
  • Hemolysis (immunology)
  • Humans
  • Male
  • Time Factors
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: